After primary PCI was completed, intracoronary nitroglycerin (100-200 μg) was administered and a coronary pressure wire (St. Jude Medical) was calibrated, equalized to the guide catheter Background-Most methods for assessing microvascular function are not readily available in the cardiac catheterization laboratory. The aim of this study is to determine whether the Index of Microcirculatory Resistance (IMR), measured at the time of primary percutaneous coronary intervention, is predictive of death and rehospitalization for heart failure. Methods and Results-IMR was measured immediately after primary percutaneous coronary intervention in 253 patients from 3 institutions with the use of a pressure-temperature sensor wire. The primary end point was the rate of death or rehospitalization for heart failure. The prognostic value of IMR was compared with coronary flow reserve, TIMI myocardial perfusion grade, and clinical variables. The mean IMR was 40.3±32.5. Patients with an IMR >40 had a higher rate of the primary end point at 1 year than patients with an IMR ≤40 (17.1% versus 6.6%; P=0.027). During a median follow-up period of 2.8 years, 13.8% experienced the primary end point and 4.3% died. An IMR >40 was associated with an increased risk of death or rehospitalization for heart failure (hazard ratio [HR], 2.1; P=0.034) and of death alone (HR, 3.95; P=0.028). On multivariable analysis, independent predictors of death or rehospitalization for heart failure included IMR >40 (HR, 2.2; P=0.026), fractional flow reserve ≤0.8 (HR, 3.24; P=0.008), and diabetes mellitus (HR, 4.4; P<0.001). An IMR >40 was the only independent predictor of death alone (HR, 4.3; P=0.02). Conclusions-An elevated IMR at the time of primary percutaneous coronary intervention predicts poor long-term outcomes.
C oronary microvascular dysfunction resulting from ST-segment elevation myocardial infarction (STEMI) portends a poor prognosis. 1, 2 Noninvasive methods are considered the reference standard for diagnosing acute microvascular dysfunction in this setting. 3, 4 However, these methods are not readily available at the time of primary percutaneous coronary intervention (PCI), the preferred initial therapy for STEMI. The Index of Microcirculatory Resistance (IMR) is a readily available, quantitative and reproducible, wire-based method for invasively assessing coronary microvascular function independent of the epicardial artery in the cardiac catheterization laboratory. [5] [6] [7] We and others have demonstrated that IMR measured at the time of STEMI correlates with infarct size and predicts the recovery of left ventricular function. [8] [9] [10] The long-term prognostic value of IMR measured in this setting is unknown.
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The aim of this study is to determine whether IMR predicts mortality and rehospitalization for heart failure when measured immediately after primary PCI in patients experiencing STEMI and to compare it with other commonly used methods for invasively assessing the coronary microvasculature such as coronary flow reserve and the thrombolysis in myocardial infarction (TIMI) myocardial perfusion grade (TMPG).
Methods
This is a prospective, multicenter, international study including hemodynamically stable patients presenting with STEMI within 12 hours of onset of symptoms or after failed fibrinolytic therapy, who had persistent ST-segment elevation ≥1 mm in contiguous leads on the ECG and who provided informed, written consent. Patients who required pressor support or intra-aortic balloon counterpulsation were not included. The study was approved by each site's internal review board. pressure with the pressure wire sensor positioned at the tip of the catheter, and then advanced to the distal two-thirds of the culprit vessel. Three milliliters of room temperature saline were briskly injected through the guide catheter, and the mean transit time was measured by using a previously described thermodilution technique. 11, 12 Three measurements were made and averaged. Maximal hyperemia was then induced by infusing intravenous adenosine at 140 µg/kg per min or by injecting intracoronary papaverine (10-20 mg). During maximal hyperemia, the mean transit time was measured again as described above. The mean distal coronary pressure measured with the pressure wire and mean proximal coronary pressure measured with the guide catheter were recorded during maximal hyperemia.
IMR was defined as the mean distal pressure multiplied by the mean hyperemic transit time, as previously described. 5 Coronary flow reserve was calculated by dividing the mean resting transit time by the mean hyperemic transit time, and the fractional flow reserve (FFR) was defined as the mean distal pressure divided by the mean proximal pressure during maximal hyperemia. 11, 12 The coefficient of variation for the IMR and coronary flow reserve were previously reported to be 6.9±6.5% and 18.6±9.6%, respectively. 6
Other Measures of Microvascular Function
The TMPG was assessed from the final recorded cine images after completion of the procedure as previously described. 2 If necessary, the view was adjusted so that the culprit vessel territory was not superimposed on noninfarcted regions. The duration of cine filming was prolonged by at least 3 cardiac cycles to make sure that the entire washout phase was included. TMPG was assessed during the same phase of the cardiac cycle. The images were analyzed offline independently by 2 interventional cardiologists blinded to the IMR result. Any discrepancies were resolved by consensus. The corrected TIMI frame count was defined as the number of frames necessary for the dye to reach standardized distal landmarks, as previously described. 13 The left anterior descending coronary artery frame counts were corrected by dividing by 1.7. The previously reported mean difference between 2 separate measurements for the corrected TIMI frame count was 4.7±3.9, and the overall agreement for TMPG was 0.59±0.04. 13
Clinical Follow-Up
The prespecified primary end point was the incidence of death or rehospitalization resulting from congestive heart failure, with a secondary end point of all-cause death alone. Rehospitalization for congestive heart failure was defined as hospitalization because of signs and symptoms of heart failure in conjunction with noninvasive imaging findings and a discharge diagnosis of congestive heart failure. Follow-up was performed by clinic visit, medical record review and telephone contact.
Statistics
Results are expressed as mean±standard deviation unless otherwise stated. Categorical variables were compared by using the χ 2 test. Cox proportional-hazard regression models were used to determine predictors of the clinical end points. All individual variables listed in Table 1 with probability value of <0.1 were considered for inclusion into multivariable forward stepwise models to determine the independent predictors. 
Results
Two hundred fifty-three patients were enrolled from 3 centers. There was 100% follow-up of all patients. Baseline characteristics are displayed in Table 1 . Papaverine was administered to obtain maximal hyperemia during the IMR measurement in 177 patients. There was 1 case of ventricular fibrillation, which required electric cardioversion. In 1 patient, IMR could not be calculated because of inadequate thermodilution curves. This patient was not included in the analysis. The median and mean IMR at the end of the procedure were 31 (interquartile range, 20.8-49.4) and 40±32, respectively. Eighty patients (31.6%) had an IMR >40, whereas 31 (12.3%) had an FFR ≤0.80. The ejection fraction on echocardiography performed during the initial hospitalization correlated with IMR (r=−0.31, P<0.001). The median follow-up duration was 2.8 years, and there were 11 (4.3%) deaths and 24 (9.5%) hospitalizations for heart failure.
At 1 year, patients with an IMR ≤40 had a significantly lower rate of the primary end point, death or rehospitalization for heart failure, in comparison with patients with an IMR >40 (6.6% versus 17.1%, P=0.027). Over the entire follow-up period, the rate of death or rehospitalization for heart failure was significantly lower in those patients with an IMR ≤40 in comparison with those with an IMR >40 (11.0 versus 20.0%, P=0.04) ( Figure 1A ). The rate of death was significantly lower in those patients with an IMR ≤40 than in those with an IMR >40 (2.3 versus 8.8%, P=0.04) ( Figure 1B ). In the patients who had both an IMR >40 and an FFR ≤0.80, the rate of death was 25.0% in comparison with 3.7% in those who did not meet these criteria (P=0.04). The Kaplan-Meier curves displaying the relationship between IMR >40 and survival free of death or rehospitalization for heart failure, and between IMR >40 and survival free of death are shown in Figure 2A and 2B.
The univariable and multivariable predictors of death or rehospitalization for heart failure are shown in Table 2 . An IMR >40 was a significant predictor of death or rehospitalization for heart failure (hazard ratio [HR], 2.1; 95% confidence interval [CI], 1.1-4.1; P=0.03). On multivariable analysis, an IMR > 40 was an independent predictor of death or rehospitalization for heart failure (HR, 2.2; 95% CI, 1.1-4.5; P=0.03). The other independent predictors were an FFR ≤0.8 (HR, 3.24; P=0.008) and diabetes mellitus (HR, 4.4; P<0.001). The univariable predictors of death alone are shown in Table 3 . An IMR >40 was a significant univariable predictor of death (HR, 4.0; 95% CI, 1.2-13.5; P=0.03). On multivariable analysis, IMR >40 was the only independent predictor of death (HR, 4.3; 95% CI, 1.3-15.0; P=0.02) ( Table 3 ).
An IMR value greater than the median value of 31 was a univariable predictor of death or rehospitalization for heart failure (HR, 3.1; CI, 1.4-6.6; P=0.004). On multivariable analysis, an IMR >31 was an independent predictor of death or rehospitalization for heart failure (HR, 3.1; 95% CI, 1.4-6.7; P=0.005). The median IMR was not a predictor of death alone.
Discussion
The main finding in this study is that IMR, measured at the time of primary PCI for STEMI, is an independent predictor of long-term clinical outcome, including death alone and death or rehospitalization because of congestive heart failure, whereas other common invasive methods for assessing microvascular function are not. An interesting secondary finding is that FFR measured at the same time is also predictive of clinical outcome. These findings reinforce the importance of microvascular dysfunction in determining the outcome after STEMI. They also highlight the independent effects of epicardial coronary artery disease, as assessed by FFR, and A number of previous studies have described the relationship between microvascular dysfunction occurring owing to STEMI and adverse cardiac outcomes. 1, 2 Therapies aimed specifically at treating acute microvascular dysfunction secondary to STEMI are now being developed and tested. 14 The benefit of any new therapy may be greatest if delivered acutely in patients with greater degrees of microvascular disruption. Unfortunately, previously reported methods for assessing microvascular dysfunction acutely in the cardiac catheterization laboratory such as coronary flow reserve and TMPG are qualitative, lack reproducibility, are not independent of the epicardial coronary artery, or are unwieldy and difficult to apply in this setting. 6, [15] [16] [17] IMR is a quantitative, reproducible index that is independent of epicardial coronary disease and specific for the microcirculation and that can be measured relatively easily at the time of STEMI. [5] [6] [7] [8] A normal value is generally considered to be <25. 7, 18 We and others have found that an elevated IMR at the time of STEMI predicts a larger degree of myocardial damage as assessed by cardiac enzyme elevation and noninvasive assessment with cardiac MRI or positron emission [8] [9] [10] In addition, there is less recovery of left ventricular function over time in patients with an elevated IMR. [8] [9] [10] In the current study, we extend these findings by showing that, in patients with an IMR greater than the mean value of 40, the rate of death or rehospitalization for congestive heart failure was significantly higher than in patients with an IMR ≤40 (20% versus 11%, P=0.04), and the rate of death alone was also significantly higher (8.8% versus 2.3%, P=0.04). On multivariable analysis, IMR was an independent predictor of both survival alone and survival or rehospitalization for congestive heart failure, whereas other common invasive methods for assessing the microvasculature were not. The relationship between IMR and adverse long-term outcomes is likely explained by the correlation between an elevated IMR and increased myocardial damage with greater left ventricular dysfunction. [8] [9] [10] The main clinical implication of these findings is that, by measuring IMR at the time of STEMI, one can identify the highest-risk patients who might benefit most from closer follow-up or early intervention with novel therapies aimed at microvascular recovery. For example, administration of intracoronary streptokinase has been shown to result in less microvascular damage based on IMR assessment at the time of primary PCI for STEMI. 14 Moreover, the delivery of autologous stem cells may have its greatest effect on the highest-risk patients. 19 FFR measurement in the culprit vessel at the time of STEMI is not advocated for assessing residual epicardial disease, because the acute microvascular dysfunction that occurs with STEMI may be partially reversible, resulting in an FFR value that may be lower if measured again at a later time point, when any reversible component of the microvascular dysfunction has resolved. Nevertheless, it appears that those patients who have an FFR ≤0.80 in the culprit vessel at the time of STEMI are at increased risk for future adverse events. The association between an ischemic FFR after primary PCI and decreased survival may be a result of the residual epicardial disease and its association with recurrent ischemic events. 20 Likewise, the fact that diabetes mellitus is also an independent predictor of death or rehospitalization for heart failure may reflect the impact of diabetes mellitus on both epicardial coronary artery disease and microvascular dysfunction.
The limitations of this study include the lack of data regarding the extent of coronary disease in the patients included. The mortality rate in this study was lower than in other reports of patients with STEMI. 21 This suggests that the patients included in this study may represent a lower-risk population. One would expect, however, that if higher-risk patients had been included, the negative prognostic value of a high IMR would only be more pronounced. Finally, the number of events in this study was relatively small; the findings will need to be confirmed in a larger study.
Conclusions
In conclusion, this study demonstrates that IMR measured at the time of primary PCI for STEMI predicts longer-term clinical outcomes such as death and rehospitalization for heart failure. IMR may be a useful method for identifying a high-risk cohort of patients who would benefit most from novel therapies to salvage acutely damaged myocardium. 
